MXJL02000046A - Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas. - Google Patents

Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.

Info

Publication number
MXJL02000046A
MXJL02000046A MXJL02000046A MXJL02000046A MXJL02000046A MX JL02000046 A MXJL02000046 A MX JL02000046A MX JL02000046 A MXJL02000046 A MX JL02000046A MX JL02000046 A MXJL02000046 A MX JL02000046A MX JL02000046 A MXJL02000046 A MX JL02000046A
Authority
MX
Mexico
Prior art keywords
vitreous
treatment
hemorrhages
injectable solution
intravitreous
Prior art date
Application number
MXJL02000046A
Other languages
English (en)
Inventor
Jimenez Bayardo Arturo
Original Assignee
Jimenez Bayardo Arturo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jimenez Bayardo Arturo filed Critical Jimenez Bayardo Arturo
Priority to MXJL02000046A priority Critical patent/MXJL02000046A/es
Priority to PCT/MX2003/000093 priority patent/WO2004054589A1/es
Priority to EP03772926A priority patent/EP1582212A1/en
Priority to AU2003279592A priority patent/AU2003279592A1/en
Priority to US10/538,815 priority patent/US20060116428A1/en
Publication of MXJL02000046A publication Critical patent/MXJL02000046A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invencion se relaciona con una solucion oftalmica para la aclaracion de hemorragias vitreas. Mas especificamente, se trata de una solucion inyectable intraocular, farmaceuticamente aceptable, para el tratamiento de la hemorragia vitrea, mediante la cual se promueve la reabsorcion de dicha hemorragia. Con ello se posibilita la aclaracion de la hemorragia vitrea en un periodo de tiempo significativamente corto para permitir el diagnostico oportuno de la lesion y la reparacion del dano que ha producido la hemorragia en el cuerpo vitreo. La solucion oftalmica de la presente invencion se inyecta al menos una vez en el humor vitreo del paciente en una dosis terapeuticamente efectiva para obtener el resultado deseado.
MXJL02000046A 2002-12-13 2002-12-13 Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas. MXJL02000046A (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXJL02000046A MXJL02000046A (es) 2002-12-13 2002-12-13 Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.
PCT/MX2003/000093 WO2004054589A1 (es) 2002-12-13 2003-10-30 Solucion inyectable intravitrea para el tratamiento de hemorragias vítreas
EP03772926A EP1582212A1 (en) 2002-12-13 2003-10-30 Intravitreally-injectable solution for the treatment of vitreous haemorrhages
AU2003279592A AU2003279592A1 (en) 2002-12-13 2003-10-30 Intravitreally-injectable solution for the treatment of vitreous haemorrhages
US10/538,815 US20060116428A1 (en) 2002-12-13 2003-10-30 Intravitreally-injectable solution for the treatment of vitreous hemorrhages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXJL02000046A MXJL02000046A (es) 2002-12-13 2002-12-13 Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.

Publications (1)

Publication Number Publication Date
MXJL02000046A true MXJL02000046A (es) 2004-06-24

Family

ID=32589022

Family Applications (1)

Application Number Title Priority Date Filing Date
MXJL02000046A MXJL02000046A (es) 2002-12-13 2002-12-13 Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.

Country Status (5)

Country Link
US (1) US20060116428A1 (es)
EP (1) EP1582212A1 (es)
AU (1) AU2003279592A1 (es)
MX (1) MXJL02000046A (es)
WO (1) WO2004054589A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3014633C (en) 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
CA2764635C (en) * 2009-06-09 2018-05-22 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
EP2875811A1 (en) * 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2067418B1 (es) * 1993-07-16 1995-11-01 Univ Valladolid Nueva aplicacion de la interleukina-1 beta recombinante humana en el campo de la oftalmologia.
TW274516B (es) * 1993-11-12 1996-04-21 Ciba Geigy Ag
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
MX9701946A (es) * 1997-03-14 1998-04-30 Arturo Jimenez Bayardo Solucion oftalmica transportadora.
AU780299B2 (en) * 1999-03-02 2005-03-17 Numoda Biotechnologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye

Also Published As

Publication number Publication date
WO2004054589A1 (es) 2004-07-01
US20060116428A1 (en) 2006-06-01
AU2003279592A1 (en) 2004-07-09
EP1582212A1 (en) 2005-10-05

Similar Documents

Publication Publication Date Title
EP1671627B8 (en) Improvement of cell therapy and tissue regeneration in patients with cardiovascular and neurological diseases by means of shockwaves
EP1765362A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEOVASCULAR DISEASES
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
ITMI20021527A1 (it) Anticorpi anti componente c5 del complemento e loro uso
EA200700214A1 (ru) Мемантин в качестве дополнительной терапии к атипичным антипсихотическим средствам у больных шизофренией
EP1758998A4 (en) OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES
WO2004019884A3 (en) Agents and methods for enhancing bone formation
EP1389121A4 (en) METHODS AND COMPOSITIONS FOR TREATING MAMMARY NERVOUS TISSUE DAMAGE
EA200501023A1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
TW200509968A (en) Prevention and treatment of synucleinopathic disease
BR0316753A (pt) Método de tratamento para disfunção sexual
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
TW200518760A (en) Triamcinolone acetonide and anecortave acetate formulations for injection
WO2007096396A3 (en) Methods for treating autoimmune or demyelinating diseases
EP1543158A4 (en) REGULATED APTAMER THERAPEUTICS
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
PT1677806E (pt) Métodos para tratamento de entorse e distensão muscular aguda e por excesso de esforço utilizando ácido hialurónico
MXJL02000046A (es) Solucion inyectable intravitrea para el tratamiento de hemorragias vitreas.
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
EP1804789A4 (en) METHOD FOR TREATING PREECLAMPSY IN HUMANS WITH RESIBUFAGENIN
EA200500427A1 (ru) Способы лечения пациентов, страдающих синдромом усталых ног или связанными с ним заболеваниями
Gibson et al. The consumption of plasminogen following severe burn and its implications in muscle calcification

Legal Events

Date Code Title Description
FA Abandonment or withdrawal